510(k) device
Mor
Morari, Inc. · Non-Implanted Electrical Stimulation Device For Management Of Premature Ejaculation (QRC, Class II) · First FDA decision Feb 11, 2025, newest Feb 11, 2025Erectile dysfunction
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
2
Naming "Mor"
MAUDE reports
36
Brand "Mor", since 2015
PubMed studies
6,263
Mentioning "Mor"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Mor
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- MOR510(k)
K241897 · Decided Feb 11, 2025 · 228 days after receipt
Device type: Non-Implanted Electrical Stimulation Device For Management Of Premature Ejaculation (QRC) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Deep Brain Stimulation for Essential Tremor and Parkinson’s DiseaseNational determinationOn the books160.24Updated Nov 4, 2026
- Bariatric Surgical Management of Morbid ObesityLocal determinationIn effectL35022Novitas Solutions, Inc.Updated May 7, 2021
- Surgical Management of Morbid ObesityLocal determinationIn effectL33411First Coast Service Options, Inc.Updated Oct 2, 2019
- Tumor Antigen by Immunoassay - CA 19-9National determinationOn the books190.30Updated Oct 1, 2026
- Tumor Antigen by Immunoassay - CA 15-3/CA 27.29National determinationOn the books190.29Updated Oct 1, 2026
- Tumor Antigen by Immunoassay - CA 125National determinationOn the books190.28Updated Oct 1, 2026
- Tumor Antigen by Immunoassay CA 125 (Addition of Primary Peritoneal Adenocarcinoma as a Covered Indication)National analysisReview closedCAG-00290RUpdated Sep 24, 2026
- Positron Emission Tomography for Initial Treatment Strategy in Solid Tumors and MyelomaNational analysisReview closedCAG-00181R3Updated Sep 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Mor", any status and sponsor, newest update first.
VA Office of Research and DevelopmentFederal agency
NCT02209610 · 32 participants · Start Jul 1, 2015 · Primary completion Jan 15, 2017
Device: Electrical and Magnetic Nerve Stimulators · For: Heart Failure
Sites: Salt Lake City, Utah
University Hospital, ToursAcademic, hospital or other
NCT02302534 · 16 participants · Start Sep 2014 · Primary completion Jun 2015
Device: MRI · For: Adolescent Idiopathic Scoliosis
Sites: Tours, France
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Mor", and for the whole product code for context.
This brand
36 reports: 35 malfunction, 1 injury, 0 death
Whole product code QRC
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
- MORMalfunction
2921595-2022-00020 · Received Apr 25, 2022 · Event dated Nov 19, 2021
Device type: Implant, Endosseous, Root-Form (DZE)
Device problem as coded: Fracture; Loose or Intermittent Connection
Patient problem as coded: Failure of Implant
- MORMalfunction
2921595-2021-00049 · Received Jan 6, 2022 · Event dated Nov 11, 2021
Device type: Implant, Endosseous, Root-Form (DZE)
Device problem as coded: Osseointegration Problem
Patient problem as coded: Failure of Implant
- MORMalfunction
2921595-2021-00034 · Received Sep 17, 2021 · Event dated Aug 4, 2021
Device type: Implant, Endosseous, Root-Form (DZE)
Device problem as coded: Failure to Osseointegrate
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Mor"[tiab]. The summary above synthesizes these.
- Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.
Williams JT, Ingram SL, Henderson G, et al. · Pharmacol Rev · 2013Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- A µ-opioid receptor superagonist analgesic with minimal adverse effects.
Gomez JL, Ventriglia EN, Frangos ZJ, et al. · Nature · 2026
- Targeting the mu-Opioid Receptor for Cancer Treatment.
Zhang H, Zhou D, Gu J, et al. · Curr Oncol Rep · 2021Research Support, Non-U.S. Gov't, Review
- Mu-opioid receptor (MOR) expression in the human spiral ganglia.
Nguyen KD, Mowlds D, Lopez IA, et al. · Brain Res · 2014Research Support, N.I.H., Extramural
- MOR promotes epithelial-mesenchymal transition and proliferation via PI3K/AKT signaling pathway in human colorectal cancer.
Gao L, Yang L, He Y, et al. · Acta Biochim Biophys Sin (Shanghai) · 2022
- A diencephalic circuit in rats for opioid analgesia but not positive reinforcement.
Waung MW, Maanum KA, Cirino TJ, et al. · Nat Commun · 2022Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural
- Synthesis of MOR Zeolite/Magnetite Composite via Seed Assisted Method.
Hagio T, Nijpanich S, Kunishi H, et al. · J Nanosci Nanotechnol · 2019Research Support, Non-U.S. Gov't
- The μ-opioid receptor (MOR) promotes tumor initiation in hepatocellular carcinoma.
Li Y, Li G, Tao T, et al. · Cancer Lett · 2019Research Support, Non-U.S. Gov't
- Fentanyl-Type Antagonist of the μ-Opioid Receptor: Important Role of Axial Chirality in the Active Conformation.
Arita H, Tanaka R, Kikukawa S, et al. · J Med Chem · 2024Research Support, Non-U.S. Gov't
- Cancer-Specific Mortality Odds Ratios in the Food, Accommodation, and Beverage Activities in Italy.
Gariazzo C, Massari S, Consonni D, et al. · J Occup Environ Med · 2024Research Support, Non-U.S. Gov't
- DNMT3a methylation in neuropathic pain.
Shao C, Gao Y, Jin D, et al. · J Pain Res · 2017
- Activation of Astrocytic μ-Opioid Receptor Causes Conditioned Place Preference.
Nam MH, Han KS, Lee J, et al. · Cell Rep · 2019Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code QRC.
- vPATCHVirility Medical , Ltd. · De Novo 2023
- in2 Smart (in2S)Virility Medical , Ltd. · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.